Nebesio 2016.

Methods	RCT. Cross‐over design. Location: single tertiary centre in USA. Duration: 18 weeks, (6 weeks per treatment arm but no washout period).
Participants	Randomised 9 participants. Age, range: 4.8 to 11.6 years. Gender split: 4 males, 5 females. Diagnosis: CAH.
Interventions	Group 1: HC 15 mg/m²/day in 3 doses. Group 2: PD 3 mg/m²/day in 2 doses. Group 3: DXA 0.3 mg/m²/day in a single dose. All treatment schedules lasted 6 weeks and then switched to another one
Outcomes	Mean ACTH, androstenedione, 17 OHP concentration, IGF‐1, GH, BMI, SNP.
Notes	Outcomes reported but not presented in the review: ACTH and SNP.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	3 sequential 6‐week courses of treatment randomly assigned, but paper does not state how random sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No mention of allocation of concealment.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No mention of blinding of participants and personnel.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No mention of blinding of outcome assessments.
Incomplete outcome data (attrition bias) All outcomes	High risk	4 participants withdrew due to difficulties with peripheral IV access but it did not state which groups these participants were in when they dropped out.
Selective reporting (reporting bias)	High risk	We did not have any access to the original trial protocols to definitely confirm whether this occurred and we attempted to contact the investigators but have not received a response.Not all outcome measures listed in the 'methods' section of the paper were fully reported in the results.
Other bias	Unclear risk	We did not have any access to the original trial protocols to definitely confirm this but there was no washout period described in the paper for this cross‐over trial.